✦ LIBER ✦

Enhancing hepatitis C treatment uptake and outcomes for injection drug users

✍ Scribed by Gregory J. Dore

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 54 KB
Volume: 45
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21478

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis C virus reinfection in injecti

Hepatitis C virus reinfection in injection drug users

✍ Jason Grebely; Brian Conway; Jesse D. Raffa; Calvin Lai; Mel Krajden; Mark W. Ty 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

Spontaneous clearance of hepatitis C (HCV) may provide protection against reinfection. In a large community-based cohort study of 3,553 inner-city residents (mainly injection drug users), we identified HCV-infected individuals in whom virological clearance had occurred and compared the rate of reinf

Cost-effectiveness of hepatitis C virus

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

✍ Natasha K. Martin; Peter Vickerman; Alec Miners; Graham R. Foster; Sharon J. Hut 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a 1 ribavirin) has been shown to be costeffective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment

Hepatitis C virus load and survival amon

Hepatitis C virus load and survival among injection drug users in the United States

✍ Michie Hisada; Nilanjan Chatterjee; Zeynep Kalaylioglu; Robert J. Battjes; James 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 3 views

Persons chronically infected with hepatitis C virus (HCV), some of whom may be coinfected with HIV and human T-lymphotropic virus type II (HTLV-II), are at high risk for end-stage liver disease (ESLD). We evaluated whether ESLD death was associated with premorbid HCV RNA level or specific HCV protei

Progression of liver fibrosis among inje

Progression of liver fibrosis among injection drug users with chronic hepatitis C

✍ Lucy E. Wilson; Michael Torbenson; Jacquie Astemborski; Hawazin Faruki; Charles 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

Although most hepatitis C virus (HCV) infections are acquired by injection drug use, prospective data on the progression of liver fibrosis are sparse. Baseline liver biopsies were obtained (1996-1998) on a random sample of 210 out of 1667 HCV-positive injection drug users (IDUs). Subjects were follo

Seroprevalence of hepatitis C virus and

Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000

✍ Fan-Chen Tseng; Thomas R. O'Brien; Mingdong Zhang; Alex H. Kral; Betty A. Ortiz- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

Previous studies suggest that most injection drug users (IDUs) become infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) soon after initiating drug use. The Urban Health Study (UHS) recruited serial cross-sections of IDUs in the San Francisco Bay area from 1986 to 2005. In the current

Modeling the current and future disease

Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland

✍ Sharon J. Hutchinson; Sheila M. Bird; David J. Goldberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 2 views

Quantitative estimates of the current and future burden of hepatitis C virus (HCV) disease are required to plan a public health response to the HCV epidemic with regard to both prevention and treatment. A forward projection model was used to estimate the numbers of both current and former injecting